Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

ABSTRACT:

Background

The Clinical Treatment Score post-5 years (CTS5) is a clinicopathological tool designed to estimate late distant recurrence (LDR) in hormone receptor-positive (HR+) breast cancer patients after 5 years of adjuvant endocrine therapy (ET). While intended as a prognostic algorithm, its predictive value for ET extension remains uncertain.

Methods

The score was calculated in 4931 patients from four prospective randomized ABCSG trials (ABCSG-6, -6a, -8, and -16) with 250 LDR events. We assessed its prognostic power, calibration accuracy, and predictive value. Time to LDR was analyzed using Cox regression models.

Results

In our cohorts, the CTS5 provided prognostic information whether used as a continuous or categorical score. In the ABCSG-8 cohort (n = 2054) and

SUBMITTER: Wimmer K 

PROVIDER: S-EPMC11904565 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature